CLINICAL PROTOCOL AND DATA MANAGEMENT: ABSTRACT Part I: Clinical Protocol and Data Management (CPDM): The Clinical Trials Office (CTO) serves as a centralized resource providing CPDM services and support to the Cancer Center with the highest priority being the safety of participating patients. The CTO provides comprehensive regulatory support from protocol conception to activation, including liaison and communication with the IRB of record and sponsors to facilitate timely initiation and completion of clinical trial activities, all approval and review processes with the IRB, IND support, registration of new trials with NCI CTRP and appropriate registration and results reporting with ClinicalTrials.gov. CPDM services facilitate and optimize accrual by providing centralized and trained data management and research nurse support to KCI physicians and clinical support staff. Research coordination and protocol compliance is enhanced through fostering of physician-patient-CTO interaction, collaboration and teamwork. The CTO interfaces with several Institutional Cores (Shared Resources) to facilitate and enhance collaboration, improve processes and ensure efficient and effective use of resources. The Clinical Trial Management System OnCore is utilized to administer all clinical trial requirements. CTO supports National Clinical Trials Network, NCI-funded peer reviewed, investigator-initiated, and industry sponsored protocols. KCI/WSU is a Lead Academic Participating Site under the NCTN (U10 CA180835). Over 100 FTEs provide CPDM services as members of the CTO in support of approximately 360 active protocols. Part II: Data and Safety Monitoring (DSM): DSM is required for all types of clinical protocols; monitoring is commensurate with risk and the DSM functions are distinct from the PRMS oversight and responsibilities. Effective quality control and training is provided by the CTO to ensure compliance to the Data and Safety Monitoring Plan (DSMP). This includes coordination and administrative support to the Feasibility Review and Operations Committee (FROC), Protocol Review and Monitoring Committee (PRMC), the Data and Safety Monitoring Committee (DSMC) and the Quality Assurance Committee (QAC). Part III: Inclusion of Women and Minorities: KCI maintains and supports multiple, proactive efforts to promote the recruitment of women and minorities. These efforts have resulted in exceptional enrollment of minorities and women to interventional trials over the current grant period with 40.2% accrual of minorities and 61.4% accrual of women in 2013. Part IV: Inclusion of Children: KCI partners with Children's Hospital of Michigan to facilitate pediatric accrual to clinical trials; supporting the NIH policy and guidelines on the inclusion of children in research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-36
Application #
9384735
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
36
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Kraniak, Janice M; Chalasani, Anita; Wallace, Margaret R et al. (2018) Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Exp Neurol 299:289-298
An, Myunggi; Yu, Chunsong; Xi, Jingchao et al. (2018) Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity. Nanoscale 10:9311-9319
Neslund-Dudas, Christine M; McBride, Russell B; Kandegedara, Ashoka et al. (2018) Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. J Trace Elem Med Biol 48:233-238
Wu, Jheng-Yu; Xiang, Shengyan; Zhang, Mu et al. (2018) Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity. J Biol Chem 293:1976-1993
Negmeldin, Ahmed T; Knoff, Joseph R; Pflum, Mary Kay H (2018) The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Eur J Med Chem 143:1790-1806
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772
Matherly, Larry H; Hou, Zhanjun; Gangjee, Aleem (2018) The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemother Pharmacol 81:1-15
Pollack, Murray M; Holubkov, Richard; Reeder, Ron et al. (2018) PICU Length of Stay: Factors Associated With Bed Utilization and Development of a Benchmarking Model. Pediatr Crit Care Med 19:196-203
Bao, Xun; Wu, Jianmei; Sanai, Nader et al. (2018) A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor. J Pharm Anal 8:20-26
Heath, Elisabeth I; Lynce, Filipa; Xiu, Joanne et al. (2018) Racial Disparities in the Molecular Landscape of Cancer. Anticancer Res 38:2235-2240

Showing the most recent 10 out of 826 publications